<code id='E7CDEF5469'></code><style id='E7CDEF5469'></style>
    • <acronym id='E7CDEF5469'></acronym>
      <center id='E7CDEF5469'><center id='E7CDEF5469'><tfoot id='E7CDEF5469'></tfoot></center><abbr id='E7CDEF5469'><dir id='E7CDEF5469'><tfoot id='E7CDEF5469'></tfoot><noframes id='E7CDEF5469'>

    • <optgroup id='E7CDEF5469'><strike id='E7CDEF5469'><sup id='E7CDEF5469'></sup></strike><code id='E7CDEF5469'></code></optgroup>
        1. <b id='E7CDEF5469'><label id='E7CDEF5469'><select id='E7CDEF5469'><dt id='E7CDEF5469'><span id='E7CDEF5469'></span></dt></select></label></b><u id='E7CDEF5469'></u>
          <i id='E7CDEF5469'><strike id='E7CDEF5469'><tt id='E7CDEF5469'><pre id='E7CDEF5469'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:41
          Stock illustration of computer and medication
          Adobe

          Half a year after selling its assets at bankruptcy auction, Pear Therapeutics’ most significant digital treatments will find a new life as part of PursueCare, which provides online addiction care and mental health counseling.

          PursueCare today announced it had raised a $20 million Series B round and that it had acquired Pear’s portfolio of apps that treat people with addiction problems. PursueCare’s CEO Nick Mercadante told STAT the company hopes to develop the market for the treatments where Pear could not, by taking advantage of its access to patients and insurers.

          advertisement

          “My view of digital therapeutics is that those point solutions really need a horse to draw the carriage,” he said. “You need a willing and capable service provider that says we’re going to make this a big part of real world care and… then show the health plans how it can save them money in the real world without extra thinking.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Acelyrin, a rare IPO success, stumbles in its first big test
          Acelyrin, a rare IPO success, stumbles in its first big test

          MarkLennihan/APThebiotechcompanyAcelyrin,whichraisedmorethan$500millioninanIPOthisyear,ranintoitsfir

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Petition to FDA: Get the lead out of consumer hair dyes

          AlissaAmbrose/STATWASHINGTON—Backin1980,whentheFoodandDrugAdministrationapprovedtheuseofleadacetatei